Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | GLA | P06280 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10361540 | 0.87 | KDM4E (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10362961 | 0.85 | KDM4E (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25085840 | 0.84 | KDM4E (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13316524 | 0.84 | LMNA (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10362966 | 0.83 | KDM4E (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21580790 | 0.82 | KDM4E (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21580872 | 0.82 | CYP4F2 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10362803 | 0.80 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10361674 | 0.80 | KDM4E (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10362968 | 0.80 | KDM4E (0.46) | KDM4EGLAGAAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802549-B1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-03-01 | — | — | EP | disclosed |
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3802549-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| CN-112204037-A | Novel oxoquinolizine compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2021-01-08 | — | — | CN | disclosed |
| WO-2019228940-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-05 | — | — | WO | disclosed |
| US-6630488-B1 | Quinolizinones as integrin inhibitors | BIOCHEM PHARMA, INC. (CA) | 2003-10-07 | — | — | US | disclosed |
| EP-1115724-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | Shire Biochem Inc. (CA) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000017197-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | BIOCHEM PHARMA INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0157346-B1 | QUINOLIZINONE COMPOUND, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-01-31 | — | — | EP | disclosed |
| US-4698349-A | Quinolizinone compounds, and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-06 | — | — | US | disclosed |
| US-4650804-A | TETRAZOLYLCARBAMOYL DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-17 | — | — | US | disclosed |
| EP-0157346-A2 | Quinolizinone compound, processes for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | O60361, ARG1, QDPR | CA12 4010/4885CA1 4264/4885CA2 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.